Transplantation therapy for Parkinson's disease.
This review paper will provide an overview of the advent of neural transplantation therapy and the milestones achieved over the last 20 years for its use in treating Parkinson's disease. A discussion of technical factors that influence the outcome of neural transplantation is presented, with emphasis given on three sections dealing with immunosuppressants, alternative grafts and trophic factors which have recently been the focus of basic research and development of early phase clinical trials. Some views on the clinical assessment of transplanted Parkinson's disease patients are given at the end of the paper, with a synopsis highlighting the importance of basic research in advancing the potential clinical benefits of neural transplantation therapy in the treatment of Parkinson's disease.
Borlongan
C V
CV
Cellular Neurobiology Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA. cborlong@intra.nida.nih.gov
D000818:Animals; D016380:Brain Tissue Transplantation / Q000379:methods*; D003342:Corpus Striatum / Q000637:transplantation*; D004298:Dopamine / Q000378:metabolism*; D016332:Fetal Tissue Transplantation / Q000379:methods*; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D008636:Mesencephalon / Q000196:embryology / Q000637:transplantation*; D010300:Parkinson Disease / Q000188:drug therapy / Q000601:surgery*; D014055:Tomography, Emission-Computed
D007166:Immunosuppressive Agents; D004298:Dopamine